Delcath Systems (NASDAQ:DCTH – Get Free Report) and Stevanato Group (NYSE:STVN – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.
Earnings & Valuation
This table compares Delcath Systems and Stevanato Group’s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Delcath Systems | $2.07 million | 65.14 | -$47.68 million | ($2.97) | -1.78 |
| Stevanato Group | $1.17 billion | N/A | $157.62 million | €0.59 ($0.63) | 46.68 |
Stevanato Group has higher revenue and earnings than Delcath Systems. Delcath Systems is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
Risk & Volatility
Delcath Systems has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Stevanato Group has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500.
Profitability
This table compares Delcath Systems and Stevanato Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Delcath Systems | -2,308.86% | -563.60% | -111.13% |
| Stevanato Group | 13.43% | 14.31% | 8.18% |
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Delcath Systems and Stevanato Group, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Delcath Systems | 0 | 0 | 4 | 0 | 3.00 |
| Stevanato Group | 0 | 2 | 5 | 0 | 2.71 |
Delcath Systems presently has a consensus target price of $18.50, suggesting a potential upside of 249.06%. Given Delcath Systems’ stronger consensus rating and higher possible upside, research analysts clearly believe Delcath Systems is more favorable than Stevanato Group.
Summary
Stevanato Group beats Delcath Systems on 9 of the 13 factors compared between the two stocks.
About Delcath Systems
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
About Stevanato Group
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.
